Abstract
The indenoisoquinoline analog 4 of fagaronine chloride was prepared, as well as its positional isomer 20 [2,3,10-trimethoxy-6-methyl-9-hydroxy-11H-indeno[1,2-c]isoquinoline chloride] and the corresponding mesylated derivatives 16 [2,3,8-trimethoxy-6-methyl-9-[(methylsulfonyl)oxy]-11H-indeno [1,2,c]isoquinolin chloride]. Compounds 4, 16, and 20 were tested against P388 lymphocytic leukemia and possessed significant activity. A tricyclic analog was also synthesized and was devoid of cytotoxicity in the KB cancer cell culture system. The change in the substitution pattern of the A-ring on going from 4 to 20 was tolerated without producing a significant decrease in antitumor activity.

This publication has 11 references indexed in Scilit: